Inclusion Criteria

DISEASE CHARACTERISTICS: Histologically or cytologically proven metastatic solid tumors
that are refractory to standard therapies or for which no potentially effective therapy
exists No leukemia, lymphoma, or multiple myeloma Measurable or evaluable disease No
pleural or peritoneal effusions No symptomatic brain metastases

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At
least 12 weeks Hematopoietic: Absolute granulocyte count at least 1500/mm3 Platelet count
at least 100,000/mm3 Hemoglobin at least 9.0 g/dL Hepatic: Bilirubin normal AST and ALT no
greater than 3 times normal (no greater than 5 times normal if liver involvement present)
Albumin at least 2.5 g/dL Renal: Creatinine clearance at least 45 mL/min Other: Not
pregnant or nursing Fertile patients must use effective contraception during and for 3
months after study No active infection No concurrent serious systemic disorders Body
surface area no greater than 3.0 m2

PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent immunotherapy Chemotherapy: At
least 3 weeks since prior chemotherapy and recovered No prior LY231514 or irinotecan No
greater than 6 prior courses of a regimen containing an alkylating agent (except low dose
cisplatin) No greater than 4 prior courses of a carboplatin-containing regimen No prior
mitomycin No other concurrent chemotherapy Endocrine therapy: No concurrent hormone
therapy (except contraceptives or corticosteroids) Radiotherapy: No prior radiotherapy to
25% or more of the bone marrow No prior radiotherapy to the whole pelvis Recovered from
any prior radiotherapy No concurrent radiotherapy Surgery: Not specified Other: At least 4
weeks since any prior investigational agents No concurrent experimental medications No
aspirin or other nonsteroidal antiinflammatory agents for 2 days prior, the day of, and 2
days after the dose of LY231514 (5 days prior to LY231514 for long acting agents such as
piroxicam)